JP2023548829A5 - - Google Patents
Info
- Publication number
- JP2023548829A5 JP2023548829A5 JP2023526091A JP2023526091A JP2023548829A5 JP 2023548829 A5 JP2023548829 A5 JP 2023548829A5 JP 2023526091 A JP2023526091 A JP 2023526091A JP 2023526091 A JP2023526091 A JP 2023526091A JP 2023548829 A5 JP2023548829 A5 JP 2023548829A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- cell
- cells
- receptor
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063109829P | 2020-11-04 | 2020-11-04 | |
| US63/109,829 | 2020-11-04 | ||
| US202163172891P | 2021-04-09 | 2021-04-09 | |
| US63/172,891 | 2021-04-09 | ||
| PCT/US2021/058138 WO2022098925A1 (en) | 2020-11-04 | 2021-11-04 | Engineered ipsc and immune effector cells for heterogenous tumor control |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023548829A JP2023548829A (ja) | 2023-11-21 |
| JP2023548829A5 true JP2023548829A5 (enExample) | 2024-11-12 |
Family
ID=81458357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023526091A Pending JP2023548829A (ja) | 2020-11-04 | 2021-11-04 | 異種腫瘍制御のための操作されたｉＰＳＣ及び免疫エフェクター細胞 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230405121A1 (enExample) |
| EP (1) | EP4240832A4 (enExample) |
| JP (1) | JP2023548829A (enExample) |
| KR (1) | KR20230098637A (enExample) |
| AU (1) | AU2021376358A1 (enExample) |
| CA (1) | CA3196549A1 (enExample) |
| IL (1) | IL302476A (enExample) |
| MX (1) | MX2023004325A (enExample) |
| WO (1) | WO2022098925A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021224883A1 (en) * | 2020-02-20 | 2022-09-29 | Invenra Inc. | Bispecific GD2 and B7H2 binding molecules and methods of use |
| WO2021247794A2 (en) * | 2020-06-03 | 2021-12-09 | Regents Of The University Of Minnesota | B7h3-targeting proteins and methods of use thereof |
| US20250222029A1 (en) | 2022-04-08 | 2025-07-10 | Fate Therapeutics, Inc. | Chimeric antigen receptor for tumor targeting |
| US20250228943A1 (en) | 2022-04-08 | 2025-07-17 | Fate Therapeutics, Inc. | Cells having solid tumor targeting backbone and use thereof |
| WO2024097800A1 (en) * | 2022-11-01 | 2024-05-10 | Fate Therapeutics, Inc. | Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting kallikrein-2 |
| WO2024165051A1 (zh) * | 2023-02-09 | 2024-08-15 | 南京北恒生物科技有限公司 | 功能增强的细胞疗法 |
| WO2025180514A1 (en) * | 2024-03-01 | 2025-09-04 | Qihan Hong Kong Limited | Autoimmune disease therapy using engineered cells |
| WO2025212837A1 (en) * | 2024-04-04 | 2025-10-09 | The Regents Of The University Of Michigan | Enhanced anti-cancer t-cell therapy |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2992660A1 (en) * | 2015-07-29 | 2017-02-02 | Allergan, Inc. | Heavy chain only antibodies to ang-2 |
| US10562952B2 (en) * | 2015-09-10 | 2020-02-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD276 chimeric antigen receptors |
| US10233226B2 (en) * | 2017-06-21 | 2019-03-19 | The University Of North Carolina At Chapel Hill | Methods and compositions for chimeric antigen receptor targeting cancer cells |
| WO2019067805A1 (en) * | 2017-09-27 | 2019-04-04 | University Of Southern California | NEW PLATFORMS FOR CO-STIMULATION, NEW CAR DESIGNS AND OTHER IMPROVEMENTS FOR ADOPTIVE CELL THERAPY |
| JP2021505131A (ja) * | 2017-12-08 | 2021-02-18 | フェイト セラピューティクス，インコーポレイテッド | 増強されたｉＰＳＣ由来のエフェクター細胞を用いた免疫療法 |
| WO2019157533A1 (en) * | 2018-02-12 | 2019-08-15 | The General Hospital Corporation | Chimeric antigen receptors targeting the tumor microenvironment |
| EP3774866A1 (en) * | 2018-04-13 | 2021-02-17 | Ludwig Institute for Cancer Research Ltd | Heterodimeric inactivatable chimeric antigen receptors |
| CN114957475B (zh) * | 2018-09-26 | 2023-06-20 | 福州拓新天成生物科技有限公司 | 抗b7-h3的单克隆抗体及其在细胞治疗中的应用 |
| MX2021006194A (es) * | 2018-12-02 | 2021-06-30 | Fate Therapeutics Inc | Inmunoterapias mediante el uso de celulas efectoras potenciadas derivadas de ipsc. |
| WO2021247794A2 (en) * | 2020-06-03 | 2021-12-09 | Regents Of The University Of Minnesota | B7h3-targeting proteins and methods of use thereof |
-
2021
- 2021-11-04 EP EP21890101.5A patent/EP4240832A4/en active Pending
- 2021-11-04 WO PCT/US2021/058138 patent/WO2022098925A1/en not_active Ceased
- 2021-11-04 KR KR1020237018629A patent/KR20230098637A/ko active Pending
- 2021-11-04 US US18/250,735 patent/US20230405121A1/en active Pending
- 2021-11-04 JP JP2023526091A patent/JP2023548829A/ja active Pending
- 2021-11-04 AU AU2021376358A patent/AU2021376358A1/en active Pending
- 2021-11-04 CA CA3196549A patent/CA3196549A1/en active Pending
- 2021-11-04 MX MX2023004325A patent/MX2023004325A/es unknown
- 2021-11-04 IL IL302476A patent/IL302476A/en unknown